Two children: Jacob (-93) and Julie (-92)

Transcription

1 Curriculum Vitae - Hilde Furberg Born: Civil status: August 1, 1958, Oslo, Norway Engaged Two children: Jacob (-93) and Julie (-92) Education: Cand. Scient University of Oslo, 1982 Marketing at Norway Business School, 1989 Managing Corporate Resources, IMD 1994 Language: Norwegian, Danish, Swedish & English fluent, Some German Professional Career: From 2002 Genzyme 2010 Senior Vice President RD (Rare Diseases) EMEA Key responsibilities: Deliver EMEA P&L Sett strategic direction and targets for country organizations Liaise between Region and Global BU Competitive strategy, Planning and launching of new products in Region, including early access program Dual reporting lines to Global President RD in US and President EMEA 2006 Vice President & General Manager Nordic Benelux Maximize business opportunity for the cluster; full P&L responsibility. Deliver short and long term target, build organization with competencies needed to deliver business expectation, including launch of new products, on average 1 product pr year, orphan as well as normal drugs. Therapeutic Area: Rare Genetic Diseases, Nephrology, Endocrinology, Oncology and Biosurgery Scope: commercial, medical, regulatory, finance, distribution, HR Nordic General Manager Start and build the Nordic business. Everything from establishing legal entity, opening offices, building the organization, launching products++ all you do when you start a new business in a local market Pharmalink A/S Managing Director and part-owner, Denmark Baxter Managing Director Sweden, Coordinating CMD Nordic & Baltic, Business Unit Director Hospital Division Nordic & Baltic, Sweden Business Unit Director, Renal Division Baxter, Nordic/Baltic, Denmark Business Unit Manager Renal and Hospital Division, Norway Product Manager Diagnostica and Hospital, Norway Sales representative, South Norway Hilde Furberg Overgaden neden Vandet 33,3, 1414 København K (private) (mobile)

2 Professional Board Membership: Algeta ASA, Board Member since April 2013 ( Oslo stock exchange) Clavis, Board Member May 2012-April 2013 ( Oslo stock exchange) Pronova, Board Member May Feb 2013 (Oslo stock exchange) Copenhagen Capacity, Board Member since November 2007 (Non profitable. Attracting investment to broader CPH region, board members 50% politicians, 50% enterprises) Probi AB, Board Member (Stockholm stock exchange) Publication: Determination of trace element associated with colloidal material in seawater using INAA and RNAA. UiO, 1984 Central preparation of antibiotic admixtures including freezing and Thawing by Microwave radiation. Norwegian Pharmacy Paper, Measurement of the particle counts in different antibiotic solutions prior to and after freezing and thawing. Nor.Pharm.Acta, Effect of pretreatment with 0.9% sodium chloride or insulin solution on the delivery of insulin from an infusion system. Am J Hosp Pharm, Hilde Furberg Overgaden neden Vandet 33,3, 1414 København K (private) (mobile)

3 1 CURRICULUM VITAE, Stener Kvinnsland Vitae: Age and social status: 66 years, married, 4 children, 12 grandchildren Education: June, 1967: June, 1973: June 1973: March, 1980: January, 1986: High school degree Medical degree (MD), University of Bergen. Associate professor, Dept. of Anatomy University of Bergen PhD. thesis: The role of cyclic AMP in the mechanism of action of estradiol. University of Bergen. Specialist in medical oncology and radiotherapy Positions and appointments: Sept., 1984: January, 1987: June, : December, : September, 1991: Consultant in Oncology, Dept. of Oncology, University of Bergen. Head of department, Dept. of Oncology, and Professor in medicine (oncology), University of Trondheim. Member of the board, Norwegian Cancer Registry Chairman, The Norwegian Breast Cancer Group Consultant in Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo, Professor in medicine (oncology), University of Trondheim (until ) Febr Dec. 94: May 1992 Sept.00 Head of Department, Department of Oncology (200 beds), The Norwegian Radiumhospital. Chairman of the board, The Norwegian Cancer Society

4 2 October, : Chairman, the Scandinavian Breast Group May, 1994 Des. 94: Oct, 1994 June 02: Januar, 1995 Sept. 96: Sept Sept.02 Sept Professor in medicine (oncology), University of Oslo. Member of Council, International Union against Cancer (UICC). Director clinical R & D, Oncology Pharmacia & Upjohn, Milan Italy. Responsability: Worldwide clinical development of cancer drugs. Professor in medicine (Oncology), University of Oslo. Head of dept., Dept. of Oncology, The Norwegian Radiumhospital. Chairman-elect, Committee of International Collaborative Activity (CICA) in International Union against Cancer (from Aug. 1998) Board Member, Photocure ASA (listed Oslo Stock Exchange) Sept Febr. 02 Senior Advicer, Norwegian Cancer Society Sept June 02 Secretary General, International Union against Cancer (UICC Geneva) Febr. 02 March 03 Febr. 02 dec. 06 April 03 dec. 06 Jan. 07 dd Oct dd Head of Dept., Dept. of Oncology and Medical physics, Haukeland Universityhospital Professor of Medicine (Oncology), Medical faculty, University of Bergen Vicepresident Bergen Hospital Trust (Helse Bergen) CEO Bergen Hospital Trust (Helse Bergen) Chair of Board, Oslo University Hospital Scientific work: Publications: 130 papers: Cell biology; growth regulation; hormone mechanism of action; carcinogenesis; epidemiology; quality of life issues; endocrine therapy (mechanism of action), endocrine therapy (pharmacological aspects), endocrine theraphy (clinical trials);

5 3 other clinical trials, organizational aspects of cancer care. Special interest: All aspects of breast cancer. Bergen, april 2015 Stener Kvinnsland MD, PhD